LitAlert ~~ GeneLit.com

    • Implications of CLSPN Variants in Cellular Function and Susceptibility to Cancer.
    • Azenha D, Hernandez-Perez S, Martin Y, Viegas MS, Martins A, Lopes MC, Lam EW, Freire R, Martins TC.
    • Cancers (Basel). 2020 Aug 24;12(9):E2396. doi: 10.3390/cancers12092396.

    • BRCA1/2 mutation status impact on autophagy and immune response: Unheralded target.
    • Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J.
    • JNCI Cancer Spectr. 2020 Aug 24; pkaa077. doi: 10.1093/jncics/pkaa077. eCollection 2020 Aug.

    • Genetic Counseling for Hereditary Gastric and Pancreatic Cancer in High-Risk Gastrointestinal Cancer Clinics: An Effective Strategy.
    • Llach J, Moreno L, Sánchez A, Herrera-Pariente C, Ocaña T, Cuatrecasas M, Rivero-Sánchez L, Moreira R, Díaz M, Jung G, Pellisé M, Castells A, Balaguer F, Carballal S, Moreira L.
    • Cancers (Basel). 2020 Aug 23;12(9):E2386. doi: 10.3390/cancers12092386.

    • Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: evidence for further locus heterogeneity.
    • Smith PS, West H, Whitworth J, Castle B, Sansbury FH, Warren AY, Woodward ER, Tischkowitz M, Maher ER.
    • Genes Chromosomes Cancer. 2020 Aug 23. doi: 10.1002/gcc.22893. Epub ahead of print.

    • Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    • Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J.
    • Ann Oncol. 2020 Aug 20:S0923-7534(20)42106-4. doi: 10.1016/j.annonc.2020.08.2098. Epub ahead of print.

    • Junshi Biosciences, Impact Therapeutics to Co-Develop PARP Inhibitor Senaparib in China.
    • [No author given]
    • Precision Oncology News. 2020 Aug 20.